This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. The FDA cleared BrainsWay D treatment of Major Depression in patients who failed to respond to one or more anti-depressants in the current episode.
Kedzior, K. K., Gellersen, H. M., Brachetti, A. K., & Berlim, M. T. (2015). Journal of Affective Disorders, 187:73–83
This review and meta-analysis paper concerns the acute effect of Brainsway® Deep TMS (Deep Transcranial Magnetic Stimulation) on major depressive disorder (MDD). The review included 9 open label studies enrolling mostly treatment resistant MDD patients. Analysis was conducted for the treatment’s effect, based on the accepted depression rating scale (HDRS), and the rate of responders, patients that achieved remission, and patients that did not complete the experiment (dropouts).
The study found that high-frequency stimulation over 20 sessions led to a significant alleviation of the depressed state in the majority of patients; and it was suggested that employing Deep TMS as an add-on to concurrent medication may increase the effectiveness of both treatments.